Di Carlo Sara, Yeung Derek, Mills Jamie, Zaitoun Abed, Cameron Iain, Gomez Dhanny
Sara Di Carlo, Department of General Surgery, University of Rome, 00185 Tor Vergata, Italy.
World J Hepatol. 2016 Dec 8;8(34):1502-1510. doi: 10.4254/wjh.v8.i34.1502.
To evaluate the outcome of patients with bilobar colorectal liver metastases (CRLM) and identify clinico-pathological variables that influenced survival.
Patients with bilobar CRLM were identified from a prospectively maintained hepatobiliary database during the study period (January 2010-June 2014). Collated data included demographics, primary tumour treatment, surgical data, histopathology analysis and clinical outcome. Down-staging therapy included Oxaliplatin- or Irinotecan- based regimens, and Cetuximab was also used in patients that were wild-type. Response to neo-adjuvant therapy was assessed at the multi-disciplinary team meeting and considered for surgery if all macroscopic CRLM were resectable with a clear margin while preserving sufficient liver parenchyma.
Of the 136 patients included, thirty-two (23.5%) patients were considered inoperable and referred for palliative chemotherapy, and thirty-four (25%) patients underwent liver resection. Seventy (51.4%) patients underwent down-staging therapy, of which 37 (52.8%) patients responded sufficiently to undergo liver resection. Patients that failed to respond to down-staging therapy ( = 33, 47.1%) were referred for palliative therapy. There was a significant difference in overall survival between the three groups (surgery down-staging therapy inoperable disease, < 0.001). All patients that underwent hepatic resection, including patients that had down-staging therapy, had a significantly better overall survival compared to patients that were inoperable ( < 0.001). On univariate analysis, only resection margin significantly influenced disease-free survival ( = 0.017). On multi-variate analysis, R0 resection ( = 0.030) and female ( = 0.036) gender significantly influenced overall survival.
Patients undergoing liver resection with bilobar CRLM have a significantly better survival outcome. R0 resection is associated with improved disease-free and overall survival in this patient group.
评估双侧结直肠癌肝转移(CRLM)患者的预后,并确定影响生存的临床病理变量。
在研究期间(2010年1月至2014年6月),从一个前瞻性维护的肝胆数据库中识别出双侧CRLM患者。整理的数据包括人口统计学、原发肿瘤治疗、手术数据、组织病理学分析和临床结果。降期治疗包括基于奥沙利铂或伊立替康的方案,对于野生型患者也使用西妥昔单抗。在多学科团队会议上评估新辅助治疗的反应,如果所有宏观CRLM均可切除且切缘清晰,同时保留足够的肝实质,则考虑进行手术。
在纳入的136例患者中,32例(23.5%)患者被认为无法手术,转至姑息化疗,34例(25%)患者接受了肝切除术。70例(51.4%)患者接受了降期治疗,其中37例(52.8%)患者反应良好,得以接受肝切除术。对降期治疗无反应的患者(n = 33,47.1%)转至姑息治疗。三组患者的总生存期存在显著差异(手术组>降期治疗组>无法手术组,P<0.001)。与无法手术的患者相比,所有接受肝切除术的患者,包括接受降期治疗的患者,总生存期均显著更好(P<0.001)。单因素分析显示,只有切缘显著影响无病生存期(P = 0.017)。多因素分析显示,R0切除(P = 0.030)和女性(P = 0.036)性别显著影响总生存期。
双侧CRLM患者接受肝切除术的生存结果显著更好。R0切除与该患者组无病生存期和总生存期的改善相关。